公开(公告)号：US20240342197A1

公开(公告)日：2024-10-17

申请号：US18263205

申请日：2022-01-28

Applicant: The Johns Hopkins University ,  CReDO Science, LLC

Inventor： Ryan Vandrey ,  Ethan Russo ,  Tory Spindle

IPC: A61K31/00 ,  A61K31/015 ,  A61P25/22

CPC classification number: A61K31/658 ,  A61K31/015 ,  A61P25/22

Abstract: Non-naturally occurring compositions comprising tetrahydrocannabinol (THC) and limonene and their use for treating THC-induced anxiety and/or paranoia are disclosed.

公开(公告)号：US12109209B2

公开(公告)日：2024-10-08

申请号：US18081842

申请日：2022-12-15

Applicant: NIPPON CHEMIPHAR CO., LTD.

Inventor： Hiroshi Nagase ,  Hideaki Fujii ,  Akiyoshi Saitoh ,  Eriko Nakata ,  Masaaki Hirose ,  Isao Ooi ,  Kohei Hayashida

IPC: A61K31/485 ,  A61P25/04 ,  A61P25/06 ,  A61P25/22

CPC classification number: A61K31/485 ,  A61P25/04 ,  A61P25/06 ,  A61P25/22

Abstract: A method for therapeutic treatment of pain-associated anxiety or depression in a mammalian subject in need thereof, that includes administering to the subject an effective amount of a pharmaceutical composition containing a morphinan derivative that exhibits an opioid δ receptor agonist activity.

公开(公告)号：US20240217946A1

公开(公告)日：2024-07-04

申请号：US18289274

申请日：2022-05-24

Applicant: TASLY PHARMACEUTICAL GROUP CO., LTD.

Inventor： Xiaohui MA ,  Xucong GAO ,  Xiangyang WANG ,  Xiaoqing LI ,  Rui LIU ,  Shuiping ZHOU

IPC: C07D317/60 ,  A61K31/36 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24

CPC classification number: C07D317/60 ,  A61K31/36 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24

Abstract: The present application relates to an antidepressant and anxiolytic substituted cinnamamide compound, i.e., compound M2. The present application also provides a pharmaceutical composition containing compound M2 or a solvate thereof or a pharmaceutically acceptable salt thereof, and an antidepressant, anxiolytic, or antidepressant and anxiolytic application.

公开(公告)号：US20240207273A1

公开(公告)日：2024-06-27

申请号：US18463000

申请日：2023-09-07

Applicant: Rugen Holdings (Cayman) Limited

Inventor： Gideon Shapiro ,  Dorothy G. Flood

IPC: A61K31/519 ,  A61K9/00 ,  A61K31/444 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  A61P25/20 ,  A61P25/22

CPC classification number: A61K31/519 ,  A61K9/0019 ,  A61K31/444 ,  A61K31/497 ,  A61K31/4985 ,  A61K31/501 ,  A61K31/506 ,  A61K45/06 ,  A61P25/20 ,  A61P25/22 ,  A61K31/4545

Abstract: Disclosed are methods for treating NMDA receptor-mediated disorders by administering certain NR2B subunit-selective NMDA (N methyl-D aspartate) antagonists. NMDA receptor-mediated disorders include autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders.

公开(公告)号：US20240207232A1

公开(公告)日：2024-06-27

申请号：US18394422

申请日：2023-12-22

Applicant: Vicore Pharma AB ,  Alex Therapeutics AB

Inventor： Johan RAUD ,  Carl-Johan DALSGAARD ,  Jessica SHULL ,  Kimmy BOLKE ,  Oliver FLEETWOOD

IPC: A61K31/4178 ,  A61B5/00 ,  A61B5/08 ,  A61B5/16 ,  A61K31/138 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5513 ,  A61K31/5575 ,  A61K39/395 ,  A61P11/00 ,  A61P25/22 ,  G16H20/10 ,  G16H50/30

CPC classification number: A61K31/4178 ,  A61B5/08 ,  A61B5/165 ,  A61B5/4848 ,  A61B5/4884 ,  A61K31/138 ,  A61K31/4418 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5513 ,  A61K31/5575 ,  A61K39/3955 ,  A61P11/00 ,  A61P25/22 ,  G16H20/10 ,  G16H50/30

Abstract: Aspects of the present disclosure are directed to methods of treating a patient diagnosed with an interstitial lung disease (ILD), comprising administering a pharmaceutical drug for treating the ILD in a treatment regimen effective to treat fibrosis, inflammation, and/or vasculopathy, and in conjunction with the administration of the pharmaceutical drug, engaging in a self-directed digital therapeutic program that treats patient anxiety relating to the administration of the pharmaceutical drug, wherein the engaging in the self-directed digital therapeutic program is effective to increase adherence to the treatment regimen. Suitable pharmaceutical treatments include those that are useful in the therapy of an ILD, including pharmaceutical treatments that are in some way disease-modifying and/or capable of altering the course or the pathology of the ILD or at least slowing its progression, such as such as an antifibrotic agent, an immunomodulatory imide drug (IMID) or an angiotensin II type 2 receptor agonist (ATRAG).

公开(公告)号：US20240199682A1

公开(公告)日：2024-06-20

申请号：US18388390

申请日：2023-11-09

Applicant: Sage Therapeutics, Inc.

Inventor： Francesco G. Salituro ,  Albert Jean Robichaud ,  Gabriel Martinez Botella ,  Boyd L. Harrison ,  Andrew Griffin

IPC: C07J9/00 ,  A61P1/00 ,  A61P19/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/28 ,  A61P35/00 ,  C07J17/00 ,  C07J43/00

CPC classification number: C07J9/00 ,  A61P1/00 ,  A61P19/02 ,  A61P25/16 ,  A61P25/18 ,  A61P25/20 ,  A61P25/22 ,  A61P25/28 ,  A61P35/00 ,  C07J17/00 ,  C07J43/003

Abstract: Compounds are provided according to Formula (I):






and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

公开(公告)号：US20240189316A1

公开(公告)日：2024-06-13

申请号：US18493488

申请日：2023-10-24

Applicant: Gaba Therapeutics Inc.

Inventor： Olivier Dasse ,  Mario Saltarelli

IPC: A61K31/536 ,  A61K9/00 ,  A61P25/22

CPC classification number: A61K31/536 ,  A61K9/0053 ,  A61P25/22

Abstract: The present invention relates to deuterated etifoxine compositions and methods for administration without autoinduction of metabolism in the treatment of a variety of diseases. disorders, or conditions.

公开(公告)号：US20240166618A1

公开(公告)日：2024-05-23

申请号：US18281127

申请日：2022-03-14

Applicant: GILGAMESH PHARMACEUTICALS, INC.

Inventor： Andrew Carry KRUEGEL

IPC: C07D317/58 ,  A61K31/138 ,  A61K31/145 ,  A61K31/277 ,  A61K31/36 ,  A61P25/22 ,  A61P25/24 ,  C07C217/60 ,  C07C255/59 ,  C07C323/32

CPC classification number: C07D317/58 ,  A61K31/138 ,  A61K31/145 ,  A61K31/277 ,  A61K31/36 ,  A61P25/22 ,  A61P25/24 ,  C07C217/60 ,  C07C255/59 ,  C07C323/32

Abstract: The present disclosure provides phenalkylamine compounds and their use in treating medical disorders, such as psychiatric diseases and disorders. Pharmaceutical compositions and methods of making various phenalkylamine compounds are provided.

公开(公告)号：US20240165080A1

公开(公告)日：2024-05-23

申请号：US18411576

申请日：2024-01-12

Applicant: LOBE SCIENCES LTD.

Inventor： Yousry SAYED ,  Frederick SANCILIO ,  Philip J. Young ,  Shaileshkumar Ramanlal DESAI ,  Autumn BEAUCHAMP

IPC: A61K31/4045 ,  A61K9/00 ,  A61P25/22

CPC classification number: A61K31/4045 ,  A61K9/0053 ,  A61P25/22

Abstract: Psilocin formulations of psilocin mucate with improved stability, physical properties and/or handling characteristics, as well as enhanced pharmacologic activity, pharmacokinetic parameters and safety characteristics as compared to psilocin or psilocybin and methods for their use are provided.

公开(公告)号：US20240156904A1

公开(公告)日：2024-05-16

申请号：US18279961

申请日：2022-02-07

Applicant: SHANGHAI MENTAL HEALTH CENTER (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENTER)

Inventor： Zhen Wang ,  Dongdong Shi ,  Yingdan Zhang

IPC: A61K38/17 ,  A61P25/22 ,  A61P25/24

CPC classification number: A61K38/1754 ,  A61P25/22 ,  A61P25/24

Abstract: An application of insulin-like growth factor-binding protein 2 (IGFBP2) in the preparation of drugs for resisting mental disorders caused by early-life stress. IGFBP2 puberty intervention and adult intervention can significantly improve anxiety and depression behaviors caused by early life stress.